Reacción a "Reaction: clinical trial tests oncolytic viruses against breast cancer"

This is an article on the clinical efficacy of combination T-VEC virus and chemotherapy administered before surgery (neoadjuvant) for operable triple-negative breast tumours (non-metastatic). The rate of residual tumour at the time of surgery is assessed.  

The key is to know what response rates the same chemotherapy alone (without the virus) gives and whether the advantage provided by the virus is statistically significant. This should be assessed by an oncologist with expertise in triple negative breast cancer (I am a laboratory researcher). From what the authors say the rate obtained is higher, but due to the low number of patients nothing significant is reached and they only dare to say that the combination "may increase" the response rate, so I am afraid that an increase in the response rate is not demonstrated.